Company family
Essential: medicine shortages
As of 2 Nov 2026, 4 Essential products have a reported shortage across 2 countries, covering 4 medicines.
Products short4rank #350 of 464
Medicines4active ingredients
Countries2/16
New in 90 days20 vs market pace
Typical duration3 monthsmedian so far
Manufacturing50%demand-driven 25%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Apraclonidine | 1 | 1 Jun 2026 | Increased demand | 1/16 | |
| Colistin | 1 | 1 Apr 2025 | Other | 6/16 | |
| Haloperidol | 1 | 14 Oct 2026 | Manufacturing problem | 4/16 | |
| Methylergometrine | 1 | 1 Oct 2026 | Manufacturing problem | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.